Cumberland Pharmaceuticals Inc. (CPIX)

In Q2 2025, Cumberland announced $10.8 million in net revenues, a 10% increase, and positive results from its Phase 2 FIGHT DMD trial. In Q3 2025, the company reported $8.3 million in net revenues, with the stock declining 12.4% following the announcement. Cumberland also announced a strategic partnership with RedHill Biopharma Ltd. for Talicia and new supply agreements for Vibativ. As of November 20, 2025, the stock price was $1.91 per share, an increase of 80.19% from the previous year, but experienced a -58.61% change over the last 6 months.

The provided information does not explicitly state any demand seasonality for Cumberland Pharmaceuticals Inc.'s products and services. However, the CEO noted that the fourth quarter is often the company's strongest, suggesting some level of seasonality with higher demand in the last quarter.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products, addressing unmet medical needs in hospital acute care, gastroenterology, and oncology. Its portfolio includes Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Sancuso, Vaprisol, and Vibativ. The company is also advancing its pipeline with drug candidates like ifetroban.

Cumberland Pharmaceuticals Inc. is headquartered in Nashville, Tennessee, and primarily focuses on the U.S. market, promoting its products through its hospital, field, and oncology sales divisions. The company also establishes international partnerships to register and provide medicines in other countries, including the launch of Vibativ in Saudi Arabia and its approval in China, as well as Caldolor's approval in Mexico.

There is no explicit information detailing Cumberland Pharmaceuticals Inc.'s overall brand reputation. However, the company's focus on developing and commercializing FDA-approved products and positive clinical trial results generally contribute to a positive perception. The strategic partnership to commercialize Talicia also suggests a commitment to high-quality therapies.

Cumberland Pharmaceuticals Inc. has a mixed ownership structure, with approximately 15.07% of the company's stock owned by institutional investors, 41.59% by insiders, and 43.34% by public companies and individual investors. Insider sentiment for CPIX is positive, with insiders collectively buying approximately $9K worth of shares over the last year.